<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BICALUTAMIDEÂ - bicalutamideÂ tabletÂ </strong><br>SUN PHARMA GLOBAL INC.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use BICALUTAMIDE tablets safely and effectively. See full prescribing information for BICALUTAMIDE tablets.<br><br>BICALUTAMIDE Tablets, USP for Oral use<br>Initial U.S. Approval: 1995</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<br><ul class="Disc">
<li>Bicalutamide tablet 50 mg is an androgen receptor inhibitor indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D<span class="Sub">2</span> metastatic carcinoma of the prostate. </li>
<li>Bicalutamide tablet 150 mg daily is not approved for use alone or with other treatments. (<a href="#Section_1">1</a>) </li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">The recommended dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening). (<a href="#Section_2">2</a>) </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">50 mg tablets (<a href="#Section_3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> (<a href="#Section_4.1">4.1</a>) </li>
<li>Women (<a href="#Section_4.2">4.2</a>) </li>
<li>Pregnancy (<a href="#Section_4.3">4.3</a> and <a href="#Section_8.1">8.1</a>) </li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Severe hepatic injury and fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> have been observed. Monitor serum transaminase levels prior to starting treatment with bicalutamide, at regular intervals for the first four months of treatment and periodically thereafter, and for symptoms or signs suggestive of hepatic dysfunction. Use bicalutamide with caution in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#Section_5.1">5.1</a>) </li>
<li><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span> and <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span> have been reported during treatment with bicalutamide 150 mg when used as a single agent. (<a href="#Section_5.2">5.2</a>) </li>
<li>Bicalutamide is used in combination with a LHRH agonist. LHRH agonists have been shown to cause a reduction in glucose tolerance in males. Consideration should be given to monitoring blood glucose in patients receiving bicalutamide in combination with LHRH agonists. (<a href="#Section_5.3">5.3</a>) </li>
<li>Monitoring Prostate Specific Antigen (PSA) is recommended. Evaluate for clinical progression if PSA increases. (<a href="#Section_5.4">5.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Adverse reactions that occurred in more than 10% of patients receiving bicalutamide plus an LHRH-A were: <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (including general, back, pelvic and abdominal), <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. (<a href="#Section_6.1">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact CARACO Pharmaceutical Laboratories Ltd. at 1-800-818-4555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>R-bicalutamide is an inhibitor of CYP 3A4; therefore, caution should be used when bicalutamide is coadministered with CYP 3A4 substrates. (<a href="#Section_7">7</a>) </li>
<li><span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> times should be closely monitored in patient already receiving coumarin anticoagulants who are started on bicalutamide.(<a href="#Section_7">7</a>) </li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc"><li>Pediatric patients: Labeling describing pediatric clinical studies for bicalutamide is approved for AstraZeneca Pharmaceuticals LPâ€™s bicalutamide tablet. However, due to AstraZeneca Pharmaceuticals LPâ€™s marketing exclusivity rights, a description of those clinical studies is not approved for this bicalutamide labeling. (<a href="#Section_8.4">8.4</a>)</li></ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 12/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1. INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2. DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1. Dosage Adjustment in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </a></h2>
<h2><a href="#section-2.2" class="toc">2.2. Dosage Adjustment in <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </a></h2>
<h1><a href="#section-3" class="toc">3. DOSAGE FORMS &amp; STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4. CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-4.2" class="toc">4.2. Women</a></h2>
<h2><a href="#section-4.3" class="toc">4.3. Pregnancy</a></h2>
<h1><a href="#section-5" class="toc">5. WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1. <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2. <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span> and <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast Pain</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3. Glucose Tolerance</a></h2>
<h2><a href="#section-5.4" class="toc">5.4. Laboratory Tests</a></h2>
<h1><a href="#section-6" class="toc">6. ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1. Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2. Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7. DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8. USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1. Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3. Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4. Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5. Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6. <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7. <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8. Women</a></h2>
<h1><a href="#section-9" class="toc">10. OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11. DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12. CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1. Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3. Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13. NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1. Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14. CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1. Bicalutamide 50 mg Daily in Combination with an LHRH-A</a></h2>
<h2><a href="#section-13.2" class="toc">14.2. Safety Data from Clinical Studies using Bicalutamide 150 mg</a></h2>
<h1><a href="#section-14" class="toc">16. HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1. Storage and Handling</a></h2>
<h1><a href="#section-15" class="toc">17. PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1. INDICATIONS AND USAGE</h1>
<p class="First"><span class="Bold">Bicalutamide tablets, USP 50 mg daily are indicated</span> for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D<span class="Sub">2</span> metastatic carcinoma of the prostate. </p>
<p><span class="Bold">Bicalutamide tablets, USP 150 mg daily are not approved</span> for use alone or with other treatments <span class="Italics">[see Clinical Studies (<a href="#Section_14.2">14.2</a>)]. </span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2. DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1. Dosage Adjustment in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </h2>
<p class="First">No dosage adjustment is necessary for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see Use in Specific Populations (<a href="#Section_8.7">8.7</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2. Dosage Adjustment in <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </h2>
<p class="First">No dosage adjustment is necessary for patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. In patients with severe liver impairment (n=4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary <span class="Italics">[see Use in Specific Populations (<a href="#Section_8.6">8.6</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3. DOSAGE FORMS &amp; STRENGTHS</h1>
<p class="First">Bicalutamide 50 mg tablets for oral administration.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4. CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Bicalutamide is contraindicated in any patient who has shown a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to the drug or any of the tabletâ€™s components. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> have been reported <span class="Italics">[see Adverse Reactions (<a href="#Section_6.2">6.2</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_4.2"></a><a name="section-4.2"></a><p></p>
<h2>4.2. Women</h2>
<p class="First">Bicalutamide has no indication for women, and should not be used in this population.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_4.3"></a><a name="section-4.3"></a><p></p>
<h2>4.3. Pregnancy</h2>
<p class="First">Bicalutamide may cause fetal harm when administered to a pregnant woman. Bicalutamide is contraindicated in women, including those who are or may become pregnant. There are no studies in pregnant women using bicalutamide. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be appraised of the potential hazard to the fetus <span class="Italics">[see Use in Specific Populations (<a href="#Section_8.1">8.1</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5. WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1. <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span></h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or hospitalization due to severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> (<span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>) have been reported postmarketing in association with the use of bicalutamide. Hepatotoxicity in these reports generally occurred within the first three to four months of treatment. <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> or marked increases in liver enzymes leading to drug discontinuation occurred in approximately 1% of bicalutamide patients in controlled clinical trials.</p>
<p>Serum transaminase levels should be measured prior to starting treatment with bicalutamide, at regular intervals for the first four months of treatment, and periodically thereafter. If clinical symptoms or signs suggestive of liver dysfunction occur (e.g.,Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, â€œflu-likeâ€? symptoms, dark urine, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, or right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>), the serum transaminases, in particular the serum ALT, should be measured immediately. If at any time a patient has <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, or their ALT rises above two times the upper limit of normal, bicalutamide should be immediately discontinued with close follow-up of liver function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2. <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span> and <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast Pain</span></h2>
<p class="First">In clinical trials with bicalutamide 150 mg as a single agent for prostate cancer, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> and <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span> have been reported in up to 38% and 39% of patients, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3. Glucose Tolerance</h2>
<p class="First">A reduction in glucose tolerance has been observed in males receiving LHRH agonists. This may manifest as <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or loss of glycemic control in those with preexisting <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Consideration should therefore be given to monitoring blood glucose in patients receiving bicalutamide in combination with LHRH agonists.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4. Laboratory Tests</h2>
<p class="First">Regular assessments of serum Prostate Specific Antigen (PSA) may be helpful in monitoring the patientâ€™s response. </p>
<p>If PSA levels rise during bicalutamide therapy, the patient should be evaluated for clinical progression. For patients who have objective progression of disease together with an elevated PSA, a treatment-free period of antiandrogen, while continuing the LHRH analog, may be considered.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6. ADVERSE REACTIONS</h1>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1. Clinical Trials Experience</h2>
<p class="First">In patients with advanced prostate cancer treated with bicalutamide in combination with an LHRH analog, the most frequent adverse reaction was <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span> (53%).</p>
<p>In the multicenter, double-blind, controlled clinical trial comparing bicalutamide 50 mg once daily with flutamide 250 mg three times a day, each in combination with an LHRH analog, the following adverse reactions with an incidence of 5% or greater, regardless of causality, have been reported.</p>
<table border="0" cellpadding="0" cellspacing="0">
<caption><span>Table 1 Incidence of Adverse Reactions (â‰¥ 5% in Either Treatment Group) Regardless of Causality</span></caption>
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule">Body System <br>Adverse Reaction</th>
<th class="Lrule Rrule Toprule" align="center" colspan="2">Treatment Group <br>Number of Patients (%)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule"></th>
<th class="Lrule Rrule Toprule" align="center">Bicalutamide Plus LHRH Analog<br>(n=401)</th>
<th class="Lrule Rrule Toprule" align="center">Flutamide Plus LHRH Analog<br>(n=407)</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="3">
<span class="Sup">â€  </span>Increased liver enzyme test includes increases in AST, ALT or both. <br> â€¡ <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> includes <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, hypochronic-and <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">iron deficiency anemia</span>.<br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Body as a Whole</span><br>
</td>
<td class="Rrule" align="center" valign="top">Â  <br>
</td>
<td class="Rrule" align="center" valign="top">Â  <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> (General) <br>
</td>
<td class="Rrule" align="center" valign="top">142 (35)<br>
</td>
<td class="Rrule" align="center" valign="top">127 (31)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span> <br>
</td>
<td class="Rrule" align="center" valign="top">102 (25)<br>
</td>
<td class="Rrule" align="center" valign="top">105 (26)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">89 (22)<br>
</td>
<td class="Rrule" align="center" valign="top">87 (21)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">Pelvic Pain</span> <br>
</td>
<td class="Rrule" align="center" valign="top">85 (21)<br>
</td>
<td class="Rrule" align="center" valign="top">70 (17)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> <br>
</td>
<td class="Rrule" align="center" valign="top">71(18)<br>
</td>
<td class="Rrule" align="center" valign="top">57 (14)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span> <br>
</td>
<td class="Rrule" align="center" valign="top">46 (11)<br>
</td>
<td class="Rrule" align="center" valign="top">46 (11)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span> <br>
</td>
<td class="Rrule" align="center" valign="top">34 (8)<br>
</td>
<td class="Rrule" align="center" valign="top">34 (8)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> <br>
</td>
<td class="Rrule" align="center" valign="top">29 (7)<br>
</td>
<td class="Rrule" align="center" valign="top">27 (7)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu Syndrome</span> <br>
</td>
<td class="Rrule" align="center" valign="top">28 (7)<br>
</td>
<td class="Rrule" align="center" valign="top">30 (7)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Cardiovascular</span><br>
</td>
<td class="Rrule" align="center" valign="top">Â  <br>
</td>
<td class="Rrule" align="center" valign="top">Â  <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot Flashes</span> <br>
</td>
<td class="Rrule" align="center" valign="top">211 (53)<br>
</td>
<td class="Rrule" align="center" valign="top">217 (53)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> <br>
</td>
<td class="Rrule" align="center" valign="top">34 (8)<br>
</td>
<td class="Rrule" align="center" valign="top">29 (7)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Digestive</span><br>
</td>
<td class="Rrule" align="center" valign="top">Â  <br>
</td>
<td class="Rrule" align="center" valign="top">Â  <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> <br>
</td>
<td class="Rrule" align="center" valign="top">87 (22)<br>
</td>
<td class="Rrule" align="center" valign="top">69 (17)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> <br>
</td>
<td class="Rrule" align="center" valign="top">62 (15)<br>
</td>
<td class="Rrule" align="center" valign="top">58 (14)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> <br>
</td>
<td class="Rrule" align="center" valign="top">49 (12)<br>
</td>
<td class="Rrule" align="center" valign="top">107 (26)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Increased Liver Enzyme Test<span class="Sup">â€ </span><br>
</td>
<td class="Rrule" align="center" valign="top">30 (7)<br>
</td>
<td class="Rrule" align="center" valign="top">46 (11)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">30 (7)<br>
</td>
<td class="Rrule" align="center" valign="top">23 (6)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span> <br>
</td>
<td class="Rrule" align="center" valign="top">26 (6)<br>
</td>
<td class="Rrule" align="center" valign="top">22 (5)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">25 (6)<br>
</td>
<td class="Rrule" align="center" valign="top">29 (7)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> <br>
</td>
<td class="Rrule" align="center" valign="top">24 (6)<br>
</td>
<td class="Rrule" align="center" valign="top">32 (8)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Hemic and Lymphatic</span><br>
</td>
<td class="Rrule" align="center" valign="top">Â  <br>
</td>
<td class="Rrule" align="center" valign="top">Â  <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span><span class="Sup">â€¡</span><br>
</td>
<td class="Rrule" align="center" valign="top">45 (11)<br>
</td>
<td class="Rrule" align="center" valign="top">53 (13)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Metabolic and </span><br><span class="Bold">Nutritional</span><br>
</td>
<td class="Rrule" align="center" valign="top">Â  <br>
</td>
<td class="Rrule" align="center" valign="top">Â  <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span> <br>
</td>
<td class="Rrule" align="center" valign="top">53 (13)<br>
</td>
<td class="Rrule" align="center" valign="top">42 (10)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Loss</span> <br>
</td>
<td class="Rrule" align="center" valign="top">30 (7)<br>
</td>
<td class="Rrule" align="center" valign="top">39 (10)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">26 (6)<br>
</td>
<td class="Rrule" align="center" valign="top">27 (7)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Alkaline Phosphatase <br>Increased <br>
</td>
<td class="Rrule" align="center" valign="top">22 (5)<br>
</td>
<td class="Rrule" align="center" valign="top">24 (6)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> <br>
</td>
<td class="Rrule" align="center" valign="top">22 (5)<br>
</td>
<td class="Rrule" align="center" valign="top">18 (4)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Musculoskeletal </span><br>
</td>
<td class="Rrule" align="center" valign="top">Â  <br>
</td>
<td class="Rrule" align="center" valign="top">Â  <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Bone Pain</span> <br>
</td>
<td class="Rrule" align="center" valign="top">37 (9)<br>
</td>
<td class="Rrule" align="center" valign="top">43 (11)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Myasthenia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">27 (7)<br>
</td>
<td class="Rrule" align="center" valign="top">19 (5)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span> <br>
</td>
<td class="Rrule" align="center" valign="top">21 (5)<br>
</td>
<td class="Rrule" align="center" valign="top">29 (7)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="73571" conceptname="Pathological fracture">Pathological Fracture</span> <br>
</td>
<td class="Rrule" align="center" valign="top">17 (4)<br>
</td>
<td class="Rrule" align="center" valign="top">32 (8)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Nervous System </span><br>
</td>
<td class="Rrule" align="center" valign="top">Â  <br>
</td>
<td class="Rrule" align="center" valign="top">Â  <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> <br>
</td>
<td class="Rrule" align="center" valign="top">41 (10)<br>
</td>
<td class="Rrule" align="center" valign="top">35 (9)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">31 (8)<br>
</td>
<td class="Rrule" align="center" valign="top">40 (10)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">27 (7)<br>
</td>
<td class="Rrule" align="center" valign="top">39 (10)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> <br>
</td>
<td class="Rrule" align="center" valign="top">20 (5)<br>
</td>
<td class="Rrule" align="center" valign="top">9 (2)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> <br>
</td>
<td class="Rrule" align="center" valign="top">16 (4)<br>
</td>
<td class="Rrule" align="center" valign="top">33 (8)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Respiratory System </span><br>
</td>
<td class="Rrule" align="center" valign="top">Â  <br>
</td>
<td class="Rrule" align="center" valign="top">Â  <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span> <br>
</td>
<td class="Rrule" align="center" valign="top">51 (13)<br>
</td>
<td class="Rrule" align="center" valign="top">32 (8)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough Increased</span> <br>
</td>
<td class="Rrule" align="center" valign="top">33 (8)<br>
</td>
<td class="Rrule" align="center" valign="top">24 (6)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> <br>
</td>
<td class="Rrule" align="center" valign="top">32 (8)<br>
</td>
<td class="Rrule" align="center" valign="top">23 (6)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span> <br>
</td>
<td class="Rrule" align="center" valign="top">24 (6)<br>
</td>
<td class="Rrule" align="center" valign="top">22 (3)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">18 (4)<br>
</td>
<td class="Rrule" align="center" valign="top">19 (5)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span> <br>
</td>
<td class="Rrule" align="center" valign="top">15 (4)<br>
</td>
<td class="Rrule" align="center" valign="top">22 (5)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Skin and Appendages </span><br>
</td>
<td class="Rrule" align="center" valign="top">Â  <br>
</td>
<td class="Rrule" align="center" valign="top">Â  <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> <br>
</td>
<td class="Rrule" align="center" valign="top">35 (9)<br>
</td>
<td class="Rrule" align="center" valign="top">30 (7)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span> <br>
</td>
<td class="Rrule" align="center" valign="top">25 (6)<br>
</td>
<td class="Rrule" align="center" valign="top">20 (5)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Urogenital </span><br>
</td>
<td class="Rrule" align="center" valign="top">Â  <br>
</td>
<td class="Rrule" align="center" valign="top">Â  <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">Nocturia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">49 (12)<br>
</td>
<td class="Rrule" align="center" valign="top">55 (14)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span> <br>
</td>
<td class="Rrule" align="center" valign="top">48 (12)<br>
</td>
<td class="Rrule" align="center" valign="top">26 (6)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span> <br>
</td>
<td class="Rrule" align="center" valign="top">35 (9)<br>
</td>
<td class="Rrule" align="center" valign="top">36 (9)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">36 (9)<br>
</td>
<td class="Rrule" align="center" valign="top">30 (7)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span> <br>
</td>
<td class="Rrule" align="center" valign="top">27 (7)<br>
</td>
<td class="Rrule" align="center" valign="top">35 (9)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast Pain</span> <br>
</td>
<td class="Rrule" align="center" valign="top">23 (6)<br>
</td>
<td class="Rrule" align="center" valign="top">15 (4)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary Frequency</span> <br>
</td>
<td class="Rrule" align="center" valign="top">23 (6)<br>
</td>
<td class="Rrule" align="center" valign="top">29 (7)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span> <br>
</td>
<td class="Rrule" align="center" valign="top">20 (5)<br>
</td>
<td class="Rrule" align="center" valign="top">14 (3)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Urinary Impaired <br>
</td>
<td class="Rrule" align="center" valign="top">19 (5)<br>
</td>
<td class="Rrule" align="center" valign="top">15 (4)<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary Incontinence</span> <br>
</td>
<td class="Rrule" align="center" valign="top">15 (4)<br>
</td>
<td class="Rrule" align="center" valign="top">32 (8)<br>
</td>
</tr>
</tbody>
</table>
<p>Other adverse reactions (greater than or equal to 2%, but less than 5%) reported in the bicalutamide-LHRH analog treatment group are listed below by body system and are in order of decreasing frequency within each body system regardless of causality.</p>
<p><span class="Bold">Body as a Whole:</span> Neoplasm; <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">Neck Pain</span>; <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>; <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span>; <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span>; <span class="product-label-link" type="condition" conceptid="199860" conceptname="Hernia of abdominal cavity">Hernia</span>; <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">Cyst</span> </p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina Pectoris</span>; <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span>; <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarct</span>; <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Heart Arrest</span>; <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disorder</span>; <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> </p>
<p><span class="Bold">Digestive:</span> <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">Melena</span>; <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">Rectal Hemorrhage</span>; <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span>; <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span>; <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorder</span>; <span class="product-label-link" type="condition" conceptid="4103655" conceptname="Dental abscess">Periodontal Abscess</span>; Gastrointestinal Carcinoma </p>
<p><span class="Bold">Metabolic and Nutritional:</span> <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>; BUN Increased; Creatinine Increased; <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span>; <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout</span>; <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesteremia</span> </p>
<p><span class="Bold">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>; <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Leg Cramps</span> </p>
<p><span class="Bold">Nervous:</span> <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">Hypertonia</span>; <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span>; <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>; <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">Libido Decreased</span>; <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span>; <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span> </p>
<p><span class="Bold">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">Lung Disorder</span>; <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>; <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span>; <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> </p>
<p><span class="Bold">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry Skin</span>; <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>; <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>; <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes Zoster</span>; Skin Carcinoma; <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin Disorder</span> </p>
<p><span class="Bold">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataract specified</span> </p>
<p><span class="Bold">Urogenital:</span> <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span>; <span class="product-label-link" type="condition" conceptid="200845" conceptname="Urgent desire to urinate">Urinary Urgency</span>; <span class="product-label-link" type="condition" conceptid="433811" conceptname="Hydronephrosis">Hydronephrosis</span>; <span class="product-label-link" type="condition" conceptid="197331" conceptname="Disorder of urinary tract">Urinary Tract Disorder</span> </p>
<p><span class="Bold">Abnormal Laboratory Test Values: </span></p>
<p>Laboratory abnormalities including elevated AST, ALT, bilirubin, BUN, and creatinine and <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">decreased hemoglobin</span> and white cell count have been reported in both bicalutamide-LHRH analog treated and flutamide-LHRH analog treated patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2. Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of bicalutamide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>Uncommon cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> have been seen <span class="Italics">[see Contraindications (<a href="#Section_4.1">4.1</a>)]</span>. Cases of <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span> (some fatal), including <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span>, have been reported with bicalutamide. <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial lung disease</span> has been reported most often at doses greater than 50 mg. A few cases of fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> have been reported.</p>
<p>Reduction in glucose tolerance, manifesting as <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or a loss of glycemic control in those with preexisting <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, has been reported during treatment with LHRH agonists.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7. DRUG INTERACTIONS</h1>
<p class="First">Clinical studies have not shown any drug interactions between bicalutamide and LHRH analogs (goserelin or leuprolide). There is no evidence that bicalutamide induces hepatic enzymes. </p>
<p><span class="Italics">In vitro</span> studies have shown that R-bicalutamide is an inhibitor of CYP 3A4 with lesser inhibitory effects on CYP 2C9, 2C19 and 2D6 activity. Clinical studies have shown that with coadministration of bicalutamide, mean midazolam (a CYP 3A4 substrate) levels may be increased 1.5 fold (for C<span class="Sub">max</span>) and 1.9 fold (for AUC). Hence, caution should be exercised when bicalutamide is coadministered with CYP 3A4 substrates. </p>
<p><span class="Italics">In vitro</span> protein-binding studies have shown that bicalutamide can displace coumarin anticoagulants from binding sites. <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> times should be closely monitored in patients already receiving coumarin anticoagulants who are started on bicalutamide and adjustment of the anticoagulant dose may be necessary.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8. USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1. Pregnancy</h2>
<p class="First">PREGNANCY CATEGORY X <span class="Italics">[see Contraindications (<a href="#Section_4.3">4.3</a>)].</span> Based on its mechanism of action, bicalutamide may cause fetal harm when administered to a pregnant woman. Bicalutamide is contraindicated in women, including those who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. </p>
<p>While there are no human data on the use of bicalutamide in pregnancy and bicalutamide is not for use in women, it is important to know that maternal use of an androgen receptor inhibitor could affect development of the fetus. </p>
<p>In animal reproduction studies, male offspring of rats receiving doses of 10 mg/kg/day (approximately 2/3 of clinical exposure at the recommended dose) and above, were observed to have reduced anogenital distance and <span class="product-label-link" type="condition" conceptid="196528" conceptname="Hypospadias">hypospadias</span>. These pharmacological effects have been observed with other antiandrogens. No other teratogenic effects were observed in rabbits receiving doses up to 200 mg/kg/day (approximately 1/3 of clinical exposure at the recommended dose) or rats receiving doses up to 250 mg/kg/day (approximately 2 times the clinical exposure at the recommended dose).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3. Nursing Mothers</h2>
<p class="First">Bicalutamide is not indicated for use in women. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4. Pediatric Use</h2>
<p class="First">The safety and effectiveness of bicalutamide in pediatric patients have not been established.</p>
<p>Labeling describing pediatric clinical studies for bicalutamide is approved for AstraZeneca Pharmaceuticals LPâ€™s bicalutamide tablet.Â  However, due to AstraZeneca Pharmaceuticals LPâ€™s marketing exclusivity rights, a description of those clinical studies is not approved for this bicalutamide labeling.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5. Geriatric Use</h2>
<p class="First">In two studies in patients given 50 or 150 mg daily, no significant relationship between age and steady-state levels of total bicalutamide or the active R-enantiomer has been shown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6. <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Bicalutamide should be used with caution in patients with moderate-to-severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Bicalutamide is extensively metabolized by the liver. Limited data in subjects with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> suggest that excretion of bicalutamide may be delayed and could lead to further accumulation. Periodic liver function tests should be considered for hepatic-impaired patients on long-term therapy <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.1">5.1</a>)]. </span></p>
<p>No clinically significant difference in the pharmacokinetics of either enantiomer of bicalutamide was noted in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> as compared to healthy controls. However, the half-life of the R-enantiomer was increased approximately 76% (5.9 and 10.4 days for normal and impaired patients, respectively) in patients with severe liver disease (n=4).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7. <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> (as measured by creatinine clearance) had no significant effect on the elimination of total bicalutamide or the active R-enantiomer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.8"></a><a name="section-8.7"></a><p></p>
<h2>8.8. Women</h2>
<p class="First">Bicalutamide has not been studied in women.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>10. OVERDOSAGE</h1>
<p class="First">Long-term clinical trials have been conducted with dosages up to 200 mg of bicalutamide daily and these dosages have been well tolerated. A single dose of bicalutamide that results in symptoms of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> considered to be life threatening has not been established. </p>
<p>There is no specific antidote; treatment of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should be symptomatic. </p>
<p>In the management of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with bicalutamide, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> may be induced if the patient is alert. It should be remembered that, in this patient population, multiple drugs may have been taken. Dialysis is not likely to be helpful since bicalutamide is highly protein bound and is extensively metabolized. General supportive care, including frequent monitoring of vital signs and close observation of the patient, is indicated.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>11. DESCRIPTION</h1>
<p class="First">Bicalutamide tablets contain 50 mg of bicalutamide USP, a non-steroidal androgen receptor inhibitor with no other known endocrine activity. The chemical name is propanamide, N [4 cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-,(+-). The structural and molecular formulas are:</p>
<br><div class="Figure"><img alt="chemical-structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=427a872b-1b0b-41cf-aca2-49ce0163c7e6&amp;name=bicalutamide-struct.jpg"></div>
<p>Bicalutamide has a molecular weight of 430.37. The pKa' is approximately 12. Bicalutamide is a fine white to off white powder which is practically insoluble in water at 37Â°C (5 mg per 1000 mL), slightly soluble in chloroform and absolute ethanol, sparingly soluble in methanol, and soluble in acetone and tetrahydrofuran.</p>
<p>Bicalutamide tablet is a racemate with its antiandrogenic activity being almost exclusively exhibited by the R-enantiomer of bicalutamide; the S-enantiomer is essentially inactive.</p>
<p>The inactive ingredients of bicalutamide tablets are lactose monohydrate, sodium starch glycolate type A, povidone, magnesium stearate, hypromellose, polyethylene glycol, and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-11"></a><p></p>
<h1>12. CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1. Mechanism of Action</h2>
<p class="First">Bicalutamide is a non-steroidal androgen receptor inhibitor. It competitively inhibits the action of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> by binding to cytosol androgen receptors in the target tissue. Prostatic carcinoma is known to be androgen sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen. </p>
<p>When bicalutamide is combined with luteinizing hormone releasing hormone (LHRH) analog therapy, the suppression of serum testosterone induced by the LHRH analog is not affected. However, in clinical trials with bicalutamide as a single agent for prostate cancer, rises in serum testosterone and estradiol have been noted.</p>
<p>In a subset of patients who have been treated with bicalutamide and an LHRH agonist, and who discontinue bicalutamide therapy due to progressive advanced prostate cancer, a reduction in Prostate Specific Antigen (PSA) and/or clinical improvement (antiandrogen withdrawal phenomenon) may be observed.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3. Pharmacokinetics</h2>
<p class="First"><span class="Bold">Absorption </span></p>
<p>Bicalutamide is well-absorbed following oral administration, although the absolute bioavailability is unknown. Coadministration of bicalutamide with food has no clinically significant effect on rate or extent of absorption. </p>
<p><span class="Bold">Distribution </span></p>
<p>Bicalutamide is highly protein-bound (96%) <span class="Italics">[see Drug Interactions (<a href="#Section_7">7</a>)].</span></p>
<p><span class="Bold">Metabolism/Elimination </span></p>
<p>Bicalutamide undergoes stereospecific metabolism. The S (inactive) isomer is metabolized primarily by glucuronidation. The R (active) isomer also undergoes glucuronidation but is predominantly oxidized to an inactive metabolite followed by glucuronidation. Both the parent and metabolite glucuronides are eliminated in the urine and feces. The S-enantiomer is rapidly cleared relative to the R-enantiomer, with the R-enantiomer accounting for about 99% of total steady-state plasma levels. </p>
<p>Pharmacokinetics of the active enantiomer of bicalutamide in normal males and patients with prostate cancer are presented in Table 2.</p>
<br><table border="0" cellpadding="0" cellspacing="0">
<caption><span>Table 2</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule">Parameter </th>
<th class="Lrule Rrule Toprule" align="center">Mean </th>
<th class="Lrule Rrule Toprule" align="center">Standard<br>Deviation </th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">Normal Males (n=30) <br>
</td>
<td class="Rrule" valign="top">Â  <br>
</td>
<td class="Rrule" valign="top">Â  <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Apparent Oral Clearance (L/hr) <br>
</td>
<td class="Rrule" align="center" valign="top">0.32 <br>
</td>
<td class="Rrule" align="center" valign="top">0.103 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Single Dose Peak Concentration (mcg/mL) <br>
</td>
<td class="Rrule" align="center" valign="top">0.768 <br>
</td>
<td class="Rrule" align="center" valign="top">0.178 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Single Dose Time to <br>Peak Concentration (hours) <br>
</td>
<td class="Rrule" align="center" valign="top">31.3 <br>
</td>
<td class="Rrule" align="center" valign="top">14.6 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Half-life (days) <br>
</td>
<td class="Rrule" align="center" valign="top">5.8 <br>
</td>
<td class="Rrule" align="center" valign="top">2.29 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Patients with Prostate Cancer (n=40) <br>
</td>
<td class="Rrule" valign="top">Â  <br>
</td>
<td class="Rrule" valign="top">Â  <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">C<span class="Sub">ss</span> (mcg/mL) <br>
</td>
<td class="Rrule" align="center" valign="top">8.939 <br>
</td>
<td class="Rrule" align="center" valign="top">3.504 <br>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-12"></a><p></p>
<h1>13. NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1. Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Two-year oral carcinogenicity studies were conducted in both male and female rats and mice at doses of 5, 15 or 75 mg/kg/day of bicalutamide. A variety of tumor target organ effects were identified and were attributed to the antiandrogenicity of bicalutamide, namely, testicular benign interstitial (Leydig) cell tumors in male rats at all dose levels (the steady-state plasma concentration with the 5 mg/kg/day dose is approximately 2/3 human therapeutic concentrations*) and uterine adenocarcinoma in female rats at 75Â mg/kg/day (approximately 1 1/2 times the human therapeutic concentrations*). There is no evidence of Leydig cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> in patients; uterine tumors are not relevant to the indicated patient population.</p>
<p>A small increase in the incidence of hepatocellular carcinoma in male mice given 75Â mg/kg/day of bicalutamide (approximately 4 times human therapeutic concentrations*) and an increased incidence of benign thyroid follicular cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in rats given 5 mg/kg/day (approximately 2/3 human therapeutic concentrations*) and above were recorded. These neoplastic changes were progressions of non-neoplastic changes related to hepatic enzyme induction observed in animal toxicity studies. Enzyme induction has not been observed following bicalutamide administration in man. There were no tumorigenic effects suggestive of genotoxic carcinogenesis.</p>
<p>A comprehensive battery of both <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> genotoxicity tests (yeast gene conversion, Ames, E. coli, CHO/HGPRT, human lymphocyte cytogenetic, mouse micronucleus, and rat bone marrow cytogenetic tests) has demonstrated that bicalutamide does not have genotoxic activity. </p>
<p>Administration of bicalutamide may lead to inhibition of spermatogenesis. The long-term effects of bicalutamide on male fertility have not been studied.</p>
<p>In male rats dosed at 250 mg/kg/day (approximately 2 times human therapeutic concentrations*), the precoital interval and time to successful mating were increased in the first pairing but no effects on fertility following successful mating were seen. These effects were reversed by 7 weeks after the end of an 11-week period of dosing.</p>
<p>No effects on female rats dosed at 10, 50 and 250 mg/kg/day (approximately 2/3, 1 and 2 times human therapeutic concentrations, respectively*) or their female offspring were observed. Administration of bicalutamide to pregnant females resulted in <span class="product-label-link" type="condition" conceptid="4140373" conceptname="Feminized male">feminization</span> of the male offspring leading to <span class="product-label-link" type="condition" conceptid="196528" conceptname="Hypospadias">hypospadias</span> at all dose levels. Affected male offspring were also impotent. </p>
<p>*Based on a maximum dose of 50 mg/day of bicalutamide for an average 70 kg patient.Â  </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-13"></a><p></p>
<h1>14. CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1. Bicalutamide 50 mg Daily in Combination with an LHRH-A</h2>
<p class="First">In a multicenter, double-blind, controlled clinical trial, 813 patients with previously untreated advanced prostate cancer were randomized to receive bicalutamide 50 mg once daily (404 patients) or flutamide 250 mg (409 patients) three times a day, each in combination with LHRH analogs (either goserelin acetate implant or leuprolide acetate depot). </p>
<p>In an analysis conducted after a median follow-up of 160 weeks was reached, 213 (52.7%) patients treated with bicalutamide-LHRH analog therapy and 235 (57.5%) patients treated with flutamide-LHRH analog therapy had died. There was no significant difference in survival between treatment groups (see Figure 1). The hazard ratio for time to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (survival) was 0.87 (95% confidence interval 0.72 to 1.05).</p>
<p>Figure 1 - The Kaplan-Meier probability of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> for both antiandrogen treatment groups.</p>
<br><div class="Figure"><img alt="bicalutamide.fig1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=427a872b-1b0b-41cf-aca2-49ce0163c7e6&amp;name=bicalutamide.fig1.jpg"></div>
<br><p>There was no significant difference in time to objective <span class="product-label-link" type="condition" conceptid="4168352" conceptname="Tumor progression">tumor progression</span> between treatment groups (see Figure 2). Objective <span class="product-label-link" type="condition" conceptid="4168352" conceptname="Tumor progression">tumor progression</span> was defined as the appearance of any bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> or the worsening of any existing bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> on bone scan attributable to <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span>, or an increase by 25% or more of any existing measurable extraskeletal <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. The hazard ratio for time to progression of bicalutamide plus LHRH analog to that of flutamide plus LHRH analog was 0.93 (95% confidence interval, 0.79 to 1.1).<br>Figure 2 - Kaplan-Meier curve for time to progression for both antiandrogen treatment groups.</p>
<br><div class="Figure"><img alt="bicalutamide.fig2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=427a872b-1b0b-41cf-aca2-49ce0163c7e6&amp;name=bicalutamide.fig2.jpg"></div>
<br><p>Quality of life was assessed with self-administered patient questionnaires on <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, social functioning, emotional well being, vitality, activity limitation, bed <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>, overall health, physical capacity, general symptoms, and treatment related symptoms. Assessment of the Quality of Life questionnaires did not indicate consistent significant differences between the two treatment groups.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2. Safety Data from Clinical Studies using Bicalutamide 150 mg</h2>
<p class="First"><span class="Bold">Bicalutamide 150 mg is not approved for use either alone or with other treatments.</span></p>
<p>Two identical multicenter, randomized, open-label trials comparing bicalutamide 150 mg daily monotherapy to castration were conducted in patients that had locally advanced (T3-4, NX, MO) or metastatic (M1) prostate cancer. </p>
<p>Monotherapy â€” M1 Group </p>
<p>Bicalutamide 150 mg daily is not approved for use in patients with M1 cancer of the prostate. Based on an interim analysis of the two trials for survival, the Data Safety Monitoring Board recommended that bicalutamide treatment be discontinued in the M1 patients because the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was 25% (HR 1.25, 95% CI 0.87 to 1.81) and 31% (HR 1.31, 95% CI 0.97 to 1.77) higher in the bicalutamide treated group compared to that in the castrated group, respectively. </p>
<p>Locally Advanced (T3-4, NX, MO) Group</p>
<p>Bicalutamide 150 mg daily is not approved for use in patients with locally advanced (T3-4, NX, M0) cancer of the prostate. Following discontinuation of all M1 patients, the trials continued with the T3-4, NX, MO patients until study completion. In the larger trial (N=352), the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was 25% (HR 1.25, 95% CI 0.92 to 1.71) higher in the bicalutamide group and in the smaller trial (N=140), the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was 36% (HR 0.64, 95% CI, 0.39 to 1.03) lower in the bicalutamide group.</p>
<p>In addition to the above two studies, there are three other on-going clinical studies that provide additional safety information for bicalutamide 150 mg, a dose that is not approved for use. These are three multicenter, randomized, double-blind, parallel group trials comparing bicalutamide 150 mg daily monotherapy (adjuvant to previous therapy or under watchful waiting) with placebo, for <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or time to disease progression, in a population of 8113 patients with localized or locally advanced prostate cancer. </p>
<p>Bicalutamide 150 mg daily is not approved for use as therapy for patients with localized prostate cancer who are candidates for watchful waiting. Data from a planned subgroup analysis of two of these trials in 1627 patients with localized prostate cancer who were under watchful waiting, revealed a trend toward decreased survival in the bicalutamide arm after a median follow-up of 7.4 years. There were 294 (37.7%) <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in the bicalutamide treated patients versus 279 (32.9%) <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in the placebo treated patients (localized watchful waiting group) for a hazard ratio of 1.16 (95% CI 0.99 to 1.37).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-14"></a><p></p>
<h1>16. HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">White to off white, circular, biconvex, film-coated tablets debossed with "485" on one side and plain on other side.</p>
<p>Bottles of 30's with Child Resistant Capâ€¦â€¦â€¦â€¦..â€¦. NDC 41616-485-83</p>
<p>Bottles of 100's with Child Resistant Capâ€¦â€¦â€¦â€¦.â€¦..NDC 41616-485-88</p>
<p>Bottles of 100's with Non Child Resistant Capâ€¦..â€¦â€¦.NDC 41616-485-08</p>
<p>Bottles of 1000's with Non Child Resistant Capâ€¦â€¦â€¦.NDC 41616-485-18</p>
<div class="Section" data-sectionCode="44425-7">
<a name="Section_16.1"></a><a name="section-14.1"></a><p></p>
<h2>16.1. Storage and Handling</h2>
<p class="First">Store at 20Â° to 25Â°C (68Â° to 77Â°F); excursions permitted between 15Â° and 30Â°C (59Â° and 86Â°F) [see USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-15"></a><p></p>
<h1>17. PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be informed that therapy with bicalutamide tablets and the LHRH analog should be started at the same time and that they should not interrupt or stop taking these medications without consulting their physician. </p>
<p>During treatment with bicalutamide tablets, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> has been reported, and those patients who experience this symptom should observe caution when driving or operating machines. </p>
<p>Patients should be informed that <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, or loss of glycemic control in patients with preexisting <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> has been reported during treatment with LHRH agonists. Consideration should therefore be given to monitoring blood glucose in patients receiving bicalutamide tablets in combination with LHRH agonists. </p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="Bold">Patient Information</span></p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="Bold">Bicalutamide Tablets, USP</span></p>
<p>Read the Patient Information that comes with bicalutamide tablets before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your healthcare provider about your medical condition or your treatment. </p>
<p><span class="Bold">What are </span><span class="Bold">bicalutamide tablets? </span></p>
<p>Bicalutamide tablets are prescription medicines called androgen receptor inhibitors, used in combination with lutenizing hormone-releasing hormone (LHRH) medicines to treat stage D<span class="Sub">2</span> metastatic prostate cancer. It is not known if bicalutamide tablets are safe and effective in children. </p>
<p><span class="Bold">Who should not take bicalutamide tablets? </span></p>
<p>Do not take bicalutamide tablets if: </p>
<ul class="Disc">
<li>you are a woman. </li>
<li>you are allergic to any of the ingredients in bicalutamide tablets. See the end of this leaflet for a complete list of ingredients. </li>
</ul>
<p><span class="Bold">What should I tell my healthcare provider before taking bicalutamide tablets? </span></p>
<p>Before you take bicalutamide tablets, tell your healthcare provider about all your medical conditions including if you: </p>
<ul class="Disc">
<li>are a woman (see who should not take bicalutamide tablets). </li>
<li>are pregnant or think you may be pregnant. </li>
<li>have liver problems. </li>
<li>take a medicine to thin your blood. Ask your healthcare provider or pharmacist if you are not sure if your medicine is a blood thinner. </li>
<li>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (poor blood sugar control has been reported in people taking bicalutamide tablets in combination with LHRH medicines). </li>
</ul>
<p>Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements. Bicalutamide tablets and other medicines may affect each other causing side effects. Bicalutamide tablets may affect the way other medicines work, and other medicines may affect how bicalutamide tablets work. </p>
<p>Know the medicines you take. Keep a list of your medicines with you to show your healthcare providers when you get a new medicine.</p>
<p><span class="Bold">How should I take bicalutamide tablets? </span></p>
<ul class="Disc">
<li>Take bicalutamide tablets exactly as prescribed. </li>
<li>Take bicalutamide tablets at the same time everyday. </li>
<li>Your treatment with bicalutamide tablets should start at the same time as your treatment with the LHRH medicine. </li>
<li>If you miss a dose do not take an extra dose, take the next dose at your regular time. Do not take 2 doses at the same time. </li>
<li>Bicalutamide tablets can be taken with or without food. </li>
<li>If you take too many bicalutamide tablets, call your healthcare provider or Poison Control Center or go to the nearest hospital emergency room right away. </li>
<li>Do not stop taking bicalutamide tablets unless your healthcare provider tells you. </li>
<li>Your healthcare provider may do blood tests while you take bicalutamide tablets.</li>
<li>Your prostate cancer may get worse while taking bicalutamide tablets in combination with LHRH medicines. Regular monitoring of your prostate cancer with your healthcare provider is important to determine if your disease is worse. </li>
</ul>
<p><span class="Bold">What should I avoid while taking bicalutamide tablets? </span></p>
<p>Driving and operating machinery. Do not drive, operate machinery, or do other dangerous activities until you know how bicalutamide tablets affect you. </p>
<p><span class="Bold">What are the possible side effects of bicalutamide tablets? </span></p>
<p>Bicalutamide tablets can cause serious side effects. </p>
<p>Get medical help right away, if you have: </p>
<ul class="Disc">
<li>Trouble breathing with or without a <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. Some people who take bicalutamide tablets get an <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in the lungs called <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span>. </li>
<li>
<span class="Bold">An <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</span> Symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> include: <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> of the skin, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> (raised bumps), <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue, throat, or trouble swallowing. </li>
<li>Yellowing of the skin and eyes (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>), dark urine, right upper <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, loss of appetite, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, whole body <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. These may be symptoms of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>. </li>
<li>Poor blood sugar control can happen in people who take bicalutamide tablets in combination with LHRH medicines. </li>
<li>Enlargement of breast (<span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>) and <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>. </li>
</ul>
<p>The most common side effects of bicalutamide tablets include:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, or short periods of feeling warm and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> </li>
<li>whole body <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your back, pelvis, stomach </li>
<li>feeling weak </li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> </li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> </li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in your ankles, legs or feet </li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> </li>
<li>blood in your urine </li>
<li>waking from sleep to urinate at night </li>
<li>a decrease in red blood cells (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>) </li>
<li>feeling dizzy </li>
</ul>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. </p>
<p>These are not all the possible side effects of bicalutamide tablets. For more information, ask your healthcare provider or pharmacist. </p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</span></p>
<p><span class="Bold">HOW SHOULD I STORE BICALUTAMIDE TABLETS? </span></p>
<p>Store bicalutamide tablets at 20Â° to 25Â°C (68Â° to 77Â°F); excursions permitted between 15Â° and 30Â°C (59Â° and 86Â°F).</p>
<p>Keep bicalutamide tablets and all medicines out of the reach of children. </p>
<p><span class="Bold">General information about the safe and effective use of bicalutamide tablets. </span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. Do not use bicalutamide tablets for a condition for which it was not prescribed. Do not give bicalutamide tablets to other people, even if they have the same symptoms that you have. It may harm them. </p>
<p>This patient information leaflet summarizes the most important information about bicalutamide tablets. If you would like more information about bicalutamide tablets talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about bicalutamide tablets that is written for health professionals. For more information call 1-800-818-4555.</p>
<p><span class="Bold">What are the ingredients in bicalutamide tablets? </span></p>
<p>Active ingredients include: bicalutamide </p>
<p>Inactive ingredients include: lactose monohydrate, sodium starch glycolate type A, povidone, magnesium stearate, hypromellose, polyethylene glycol, and titanium dioxide</p>
<p>Distributed by:<br><span class="Bold">Caraco Pharmaceutical Laboratories, Ltd.</span><br>
            1150 Elijah McCoy Drive, Detroit, MI 48202</p>
<p>Manufactured by:<br><span class="Bold">Sun Pharma Laboratories Limited</span><br>
             Survey No. 259/15, Dadra-396 191,<br>
            (U.T. of D &amp; NH), India.</p>
<p>PGPI0081E<br>ISS. 08/2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 50 mg</h1>
<p class="First"><span class="Bold">NDC 41616-485-83<br>
                Bicalutamide Tablets, USP<br>
                50 mg<br>
                Rx only<br>
                30 TABLETS<br>
                Sun Pharma<br>
                Pharmacist: Dispense with Patient Information Leaflet
              </span></p>
<div class="Figure"><img alt="bicalutamide-label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=427a872b-1b0b-41cf-aca2-49ce0163c7e6&amp;name=bicalutamide-label.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BICALUTAMIDEÂ 		
					</strong><br><span class="contentTableReg">bicalutamide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:41616-485</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BICALUTAMIDE</strong> (BICALUTAMIDE) </td>
<td class="formItem">BICALUTAMIDE</td>
<td class="formItem">50Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">485</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:41616-485-83</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:41616-485-88</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:41616-485-08</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:41616-485-18</td>
<td class="formItem">1000  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA079110</td>
<td class="formItem">07/07/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>SUN PHARMA GLOBAL INC.
							(865367643)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sun Pharma Laboratories Limited</td>
<td class="formItem"></td>
<td class="formItem">650445203</td>
<td class="formItem">MANUFACTURE(41616-485), ANALYSIS(41616-485)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>91501890-f01d-496f-ae25-82ff297dbd53</div>
<div>Set id: 427a872b-1b0b-41cf-aca2-49ce0163c7e6</div>
<div>Version: 6</div>
<div>Effective Time: 20131210</div>
</div>
</div>Â <div class="DistributorName">SUN PHARMA GLOBAL INC.</div></p>
</body></html>
